Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 530549
NSE Symbol: SHILPAMED
ISIN: INE790G01031
📊 Shilpa Medicare: Key Financial Status Update - No outstanding long-term borrowings as of March 31, 2025 - Highest credit rating: A+ with Positive Outlook from India Ratings & Research (Ind-Ra) - Does not qualify as a Large Corporate under SEBI regulations as of April 9, 2026 - No fine required …
Shilpa Medicare Ltd. Amalgamation Approved by NCLT 📋 - NCLT Bangalore approved the amalgamation on February 27, 2026. - Appointed date for the merger is set as April 1, 2025. - Shilpa Therapeutics is a wholly owned subsidiary of SML. - No new shares will be issued as part of the scheme. - All emp…
📋 NCLT Approves Merger of Shilpa Medicare with Subsidiary • NCLT Bengaluru approved the amalgamation on February 27, 2026 • Appointed date for the merger is April 1, 2025 (updated from April 1, 2023) • No new shares will be issued; existing shares of the subsidiary will be cancelled • All employe…
Shilpa Medicare's Subsidiary Enters Latin America with Biosimilar Licensing Deal 🌎💊 • Shilpa Biologicals Pvt Ltd (SBPL) signed a licensing agreement with Steincares, Costa Rica. • Steincares gains exclusive rights to register, commercialize, and distribute a biosimilar across Latin America. • Sh…
Shilpa Medicare Secures Third Major International Mandate 🚀 - Shilpa Medicare updated its disclosure to align with an upcoming high-impact journal publication, clarifying the therapy targets autoimmune or alloimmune disorders. - The company entered a strategic partnership with Switzerland-based N…
Shilpa Medicare Secures Third Major International Mandate with NXI Therapeutics 🚀 - Shilpa Medicare Limited (SML) has entered into a binding agreement with Switzerland-based NXI Therapeutics AG for the development and supply of a New Chemical Entity (NCE). - The agreement covers development, manu…
Shilpa Medicare Reports Record Quarterly Revenue of ₹411 Cr 📈 • Highest quarterly revenue of ₹411 crores, up 28% YoY • 9-month revenue at ₹1,110 crores, up 14% YoY • Formulation revenue surged 50% YoY to ₹177 crores • API business grew 11% including captive use • Highest quarterly EBITDA of ₹115 …
📊 Shilpa Medicare Q3 FY26 Earnings Call Recording Now Available - Shilpa Medicare Limited uploaded the audio recording of its Q3 FY26 earnings conference call to its website. - The call was held on Friday, 30 January 2026, at 16:00 hrs. - The recording is available at: https://vbshilpa.com/invest…
Shilpa Medicare Files First Transdermal Patch ANDA 📈 $112M US Market Opportunity • Filed first transdermal patch ANDA with USFDA on February 6, 2026 • Generic version of Neupro® in six strengths (1-8 mg/24h) • Targets $112 million US market opportunity • Indicated for Parkinson's disease and Rest…
Shilpa Medicare Reports Strong Q3 Growth 📈 | Revenue Up 28% YoY, PAT Surges 72% • Q3 FY26 revenue: ₹411 crores, up 28% YoY • 9-month revenue: ₹1,110 crores, up 14% YoY • Q3 EBITDA: ₹115 crores, up 40% YoY with margins at 28% • 9-month EBITDA: ₹323 crores, up 26% YoY • Q3 PAT: ₹55 crores, up 72% Y…
Shilpa Medicare Q3 FY2026: Revenue Jumps 32.1% Standalone, 28.3% Consolidated 📈 • Standalone revenue from operations for Q3 FY2026 was ₹16,570.47 lakhs, up 32.1% from ₹12,538.66 lakhs in Q3 FY2025. • Consolidated revenue from operations for Q3 FY2026 was ₹40,972.67 lakhs, up 28.3% from ₹31,930.12…
📊 Shilpa Medicare Q3 FY26 Results Announcement: February 6, 2026 - Q3 FY26 financial results announcement date: February 6, 2026 - Earnings conference call scheduled for February 6, 2026 at 16:00 hrs (4:00 PM IST) - Dial-in numbers provided for universal access: +91 22 6280 1130 and +91 22 7115 8…
📅 Shilpa Medicare Board Meeting Set for Q3 FY26 Results • Board meeting scheduled for February 6, 2026 to consider and approve unaudited financial results (consolidated and standalone) for the quarter and nine months ended December 31, 2025 • Trading window closed from January 1, 2026, and will r…
🚀 Shilpa Medicare's Subsidiary Gains FDA Orphan Drug Designation for Rare Blood Cancer Treatment - Shilpa Medicare's subsidiary Shilpa Biologicals and partner mAbTree Biologics received FDA Orphan Drug Designation for a monoclonal antibody targeting rare blood cancers Essential Thrombocythemia (E…
Shilpa Medicare Scores 61.5 in Independent ESG Rating 🌱 - Shilpa Medicare Ltd (NSE: SHILPAMED/BSE-530549) assigned ESG score of 61.5 by SES ESG Research Pvt Ltd. - Rating based on publicly available FY 2025 data. - SES ESG Research is a SEBI-registered ESG Rating Provider (Category II). - Rating …
Shilpa Medicare Sells Canadian Subsidiary for CAD 2000 💼 - Shilpa Medicare sold its wholly owned Canadian subsidiary, Koanna Healthcare Canada Inc. - 2,84,21,020 equity shares were sold to Mr. Steve N. Slilaty for CAD 2000 - Transaction completed on January 14, 2026 - Koanna contributed only 0.03…
Shilpa Medicare Submits Key Compliance Update for Q4 2025 📄 - Shilpa Medicare Limited complied with SEBI Regulation 74(5) for the quarter ended December 31, 2025. - KFin Technologies Limited, the Registrar and Share Transfer Agent, issued a compliance certificate dated January 2, 2026. - The cert…
🚨 Delhi High Court Issues Injunction Against Shilpa Medicare Over Ruxolitinib Patent - Delhi High Court issued an ex parte ad-interim injunction against Shilpa Medicare Ltd. and subsidiaries. - Restricts manufacturing, stockpiling, exporting, or selling Ruxolitinib-based products due to patent in…
Shilpa Medicare Secures European Approval for Rotigotine Patch 🚀 - Shilpa Medicare received initial European authorization for its Rotigotine transdermal patch (1, 2, 3, 4, 6, 8 mg/24h). - Generic version of Neupro®, treating Restless Legs Syndrome and Parkinson’s disease. - Total European market…
🔍 USFDA Inspection Update: Shilpa Medicare’s Unit IV Receives 8 Observations - USFDA inspection at Shilpa Medicare’s Unit IV (Jadcherla, Telangana) concluded on Nov 21, 2025. - FDA issued Form 483 with 8 observations—none were repeat findings. - Facility produces sterile injectables, oral tablets…